Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension

RECOMMENDED

Pulmonary Hypertension

Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of Phase 2, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Am J Respir Crit Care Med

Montani D, McLaughlin VV, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Escribano Subias P, Feldman J, Meyer GM, Olsson KM, Coulet F, Manimaran S, Zhao Y, Lau A, de Oliveira Pena J, Badesch DB, Humbert M

doi: 10.1164/rccm.202409-1698OC

RECOMMENDED

Pulmonary Hypertension

Impact of elevated Pulmonary Arterial Wedge Pressure on safety and efficacy of balloon pulmonary angioplasty in the treatment of chronic thromboembolic pulmonary hypertension

★ 3 Recommended by Dr Martin Frey, Faculty Member

Chest

Szwed P, Kurzyna P, Banaszkiewicz-Cyganik M, Kędzierski P, Łomiak M, Wolański R, Wasilewski M, Florczyk M, Piłka M, Torbicki A, Kurzyna M, Darocha S

doi: 10.1016/j.chest.2025.10.017

RECOMMENDED

Pulmonary Hypertension

Effect of riociguat on exercise following balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension in Japan (THERAPY-HYBRID-BPA): a multicentre, double-blind, randomised, controlled, phase 4 trial

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lancet Respir Med

Shimokawahara H, Nishizaki M, Inami T, Kubota K, Taniguchi Y, Miyagi A, Kikuchi H, Goda A, Miyanaga S, Hashimoto H, Saito AM, Sekimizu M, Matsubara H

doi: 10.1016/S2213-2600(25)00127-4

Pulmonary Hypertension

Systematic Review of the Application of Pulmonary Hypertension Treatments in Ventricular Septal Defect, Pulmonary Atresia, and Major Aortopulmonary Collateral Arteries

J Clin Med

Hirono K, Uchida K, Ishii T, Ishida H, Takatsuki S, Fukushima H, Inai K, Hosokawa S, Ishizaki R, Sawada H, Sumitomo NF, Chida-Nagai A, Ishikawa Y, Motoki H, Yao A, Kogaki S, Yamagishi H, Doi S

doi: 10.3390/jcm15031087

RECOMMENDED

AsthmaFurther Publications

Rademikibart Treatment for Moderate-to-Severe, Uncontrolled Asthma: A Phase 2B Randomized Trial

★ 2 Recommended by Dr Martin Frey, Faculty Member

Am J Respir Crit Care Med

Kerwin E, Yang T, Su N, Guo J, Adivikolanu R, Longphre M, Wang J, Yun J, Pan W, Wei Z, Collazo R

doi: 10.1164/rccm.202409-1708OC

Pulmonary Hypertension

Study of Angiogenic Cell Therapy for Progressive Pulmonary Arterial Hypertension: Intervention with Repeat Dosing of eNOS-enhanced EPCs: the SAPPHIRE Trial

J Heart Lung Transplant

Stewart DJ, Mehta S, Chandy G, Hirani N, Granton J, Hambly N, Swiston J, Danovitch K, Sabri E, Giulivi A, Courtman DW, Fergusson DA

doi: 10.1016/j.healun.2025.05.012

Pulmonary Hypertension

Selection of patient-reported outcome measures in pulmonary arterial hypertension clinical trials: a systematic review, meta-analysis and health-related quality of life framework

Eur Respir Rev

Varian F, Burney R, Pearson C, Goh ZM, Newman J, Rawlings G, Zafar H, Kiely DG, Thompson AAR, Condliffe R, Toshner M, McCormack C, Armstrong I, Peasgood T, Carlton J, Rothman AMK

doi: 10.1183/16000617.0006-2025

RECOMMENDED

Asthma

Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Respir Med

Patel C, Sheth V, Koppula R, Kumar A, Bhate AS, Sahoo D, Jain MK, Mondal A, Parmar D, Kansagra K, Shrivastava R, Pathak H

doi: 10.1016/j.rmed.2025.108293

Pulmonary Hypertension

Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model

Adv Ther

Alsumali A, McLaughlin V, Chevure J, Klok R, Zhang W, Martinez EC, Pausch C, De Oliveira Pena J, van de Wetering G, Jootun M, Lautsch D, Hoeper MM

doi: 10.1007/s12325-025-03241-4

Related content

Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of Phase 2, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)

Impact of elevated Pulmonary Arterial Wedge Pressure on safety and efficacy of balloon pulmonary angioplasty in the treatment of chronic thromboembolic pulmonary hypertension

Effect of riociguat on exercise following balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension in Japan (THERAPY-HYBRID-BPA): a multicentre, double-blind, randomised, controlled, phase 4 trial

Systematic Review of the Application of Pulmonary Hypertension Treatments in Ventricular Septal Defect, Pulmonary Atresia, and Major Aortopulmonary Collateral Arteries

Rademikibart Treatment for Moderate-to-Severe, Uncontrolled Asthma: A Phase 2B Randomized Trial

Study of Angiogenic Cell Therapy for Progressive Pulmonary Arterial Hypertension: Intervention with Repeat Dosing of eNOS-enhanced EPCs: the SAPPHIRE Trial

Selection of patient-reported outcome measures in pulmonary arterial hypertension clinical trials: a systematic review, meta-analysis and health-related quality of life framework

Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model